Penny Stock Circle Newsletter
Tomorrow`s pick is: IMUN Dear Valued Subscriber, Get ready traders – We have a raging bull by the horns! This must-see alert is quickly developing into an incredible opportunity for traders! We are revisiting an alert which was a tremendous winner for our readers in the past! This company appears to be forming strong momentum which could prompt another lucrative surge for traders! Without delay, our new momentum alert is IMUN! Exciting news was issued recently which has put the company in the market`s spotlight once again. IMUN is on the launch pad and ready for liftoff! Begin your research right away! The action is about to heat up and you do not want to miss out! We are issuing an immediate momentum alert for IMUN (Immunovative, Inc.) which closed at $0.195 PPS today.
IMUN came back into focus recently as we observed a sudden surge of volume and market activity beginning to have a very positive affect on trading. As we began to dig up details on the company, the first thing that we noticed was that IMUN issued several phenomenal updates recently which are attracting considerable investor attention! When we combine these exciting developments with the company`s already impressive track record, we believe that a potentially lucrative scenario is at hand for our readers. IMUN appears to be a prime opportunity for traders to make the most of a company which is clearly on the right track! IMUN appears to hold enormous potential for our readers! We want everyone to be prepared to capitalize! IMUN, in partnership with Immunovative Therapies, Ltd., specializes in the development of novel immunotherapy drug products which incorporate living immune cells as the active ingredients for treatment of cancer and infectious diseases. Currently the companies are developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer. IMUN has been granted an exclusive worldwide license to commercialize products covered under Immunovative Therapies, Ltd.s current and pending patent application portfolio, as well as the rights to any future patent applications.
Imagine a world where chemotherapy is no longer necessary to reduce the size of tumors! We believe that this day is coming very soon! IMUN is working towards a therapy that decreases tumor size without the use of chemotherapy. The best part is that IMUN appears to have a leg-up on bringing this product to the market! This means that the company may be positioning to beat the big boys, such as Bristol-Myers, to the punch! Imagine the potential! This is an unbelievable opportunity for traders to participate in a company which has the ability to become one of the biggest names in the fight against cancer! IMUN has been forging ahead at a rapid pace. Just this week, the company issued several impressive updates including the announcement that Immunovative Therapies, Ltd. has upgraded their state of the art facility even further! IMUN is well on its way to becoming a leader in the cancer research industry and their string of exciting developments is igniting major interest from both the medical and investment communities! IMUN issued news on Tuesday announcing that Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd. was invited to speak at the inaugural Immunotherapies and Cancer Vaccine Congress to be held at the Sheraton Brussels Hotel on December 5-6 in Brussels, Belgium. This is excellent news which provides even more exposure for the company! We believe that this update adds even more fuel to an already phenomenal situation.
To view Tuesday`s news in its entirety, please use this link—> http://finance.yahoo.com/news/dr-michael-har-noy-present-123500402.html (http://links.mailerhub.net/Tracking/t.cY1ur-gZyk-1OkVMH5) The company issued exciting news on Monday as well! IMUN announced that Immunovative Therapies, Ltd. has secured the grant of United States Letters Patent. This is yet another exciting step toward the full production of their leading biological drug candidate, AlloStim. This is a major development which could propel IMUN through the roof in the days ahead and present traders with an opportunity at substantial gains! We have appended a portion of Monday`s news below.
This is the 12th U.S. patent issued to ITL covering its lead biological drug candidate called AlloStim with additional patents still pending. The next product in the pipeline, AlloVax, is an individualized anti-cancer vaccine which combines AlloStim with chaperone proteins called “CRCL.” CRCL technology, in-licensed from the University of Arizona and is covered by US Patent No. 6,875,849 entitled “Methods of recovering chaperone proteins and complexes thereof.” Therefore, ITL currently has 13 issued US patents with additional patents pending worldwide.
This newly issued patent broadly covers our lead drug candidate called AlloStim, which completed a 42 patient Phase I/II human trial in May 2010. Previously, the Company announced patents issued to cover AlloStim as a composition of matter. This newly issued patent covers AlloStim as a method for preparing cells for patient treatment.
To view Monday`s news in its entirety, please use this link—> http://finance.yahoo.com/news/immunovative-inc-further-enhances-intellectual-155016811.html (http://links.mailerhub.net/Tracking/t.cY1ur-gZyl-1OkVMH6) IMUN is working to make cancer a disease of the past. IMUN is a company which understands that cancer is becoming an epidemic of astounding proportions! Research shows that cancer is currently striking nearly one in two men (44%), and more than one in three women (39%). The National Cancer Institute estimates that the number of cancer cases will increase even further due to the growth and aging of the population, dramatically doubling by 2050. As you can clearly see, cancer research is not only an extremely lucrative industry, it`s also a public service.
With cancer running rampant, IMUN is quickly making a name in the expansive cancer industry. According to reports, the global cancer industry is estimated at a mind boggling $200B a year! IMUN is on the fast track to putting their therapies on the market and this is presenting an optimal scenario for investors! IMUN has astronomical potential and we want to give our readers a chance to research this monster prior to the rest of the market catching on! IMUN appears to be setting up perfectly to forge a monster momentum run! The company has fresh press in play along with rapidly increasing market interest. This is a prime opportunity for traders to take advantage of the lucrative cancer industry. All it takes is one success for a company such as IMUN to become one of the biggest names in the fight against cancer. With multiple patents already in place, IMUN appears to be on the verge of greatness. We want our readers prepared to take full advantage of what IMUN has to offer! There`s no time to delay! Begin your IMUN research immediately! Stay tuned for additional updates on IMUN as our new alert develops! Remember to trade smart, research your options, and use due diligence! Sincerely, The PennyStockCircle.com Team Disclaimer and Release of Liability We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PennyStockCircle`s sponsored advertisements do not purport to provide an analysis of any company`s financial position, operations or prospects and this is not to be construed as a recommendation by PennyStockCircle or an offer or solicitation to buy or sell any security. Neither the owner of PennyStockCircle nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer`s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit www.PennyStockCircle.com. PennyStockCircle makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.
PennyStockCircle is owned and operated by Global Marketing Media LLC. Global Marketing Media LLC has been compensated twenty five thousand dollars for a two day marketing and promotional effort on IMUN by Wall Street Relations, Inc.. Global Marketing Media LLC has not investigated the background of Wall Street Relations, Inc., the hiring company. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of IMUN of which they plan to liquidate, further understanding that the liquidation of those shares may negatively impact the share price. Any compensation received by Global Marketing Media LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of Global Marketing Media LLC may have shares and may liquidate, which may negatively affect the stock price.
Global Marketing Media LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market.
Some of the content in this release contains forward – looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company`s actual results of operation. A company`s actual performance could greatly differ from those described in any forward – looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company`s products; the company`s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company`s filings with the Securities and Exchange Commission. However, a company`s past performance does not guarantee future results.
Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PennyStockCircle makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and PennyStockCircle has no obligation to update any of the information provided. PennyStockCircle, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or pennystock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our release or on our website may not have approved certain or any statements within the website. PennyStockCircle encourages viewers to supplement the information obtained from this release and our website with independent research and other professional advice. The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.
This release may provide hyperlinks to third party websites or access to third party content. PennyStockCircle, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does PennyStockCircle control, endorse, or guarantee any content found in such sites. By accessing, viewing, or using the website or communications originating from this release, you agree that PennyStockCircle, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that PennyStockCircle, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
PennyStockCircle uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties.
You agree to hold PennyStockCircle, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. PennyStockCircle disclaims all warranties of any kind, express or implied.
We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at:www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.
Global Marketing Media P.O. Box 12208 Charleston South Carolina 29422 United States This email is intended for . To